Notable 52-Week Highs and Lows of the Day 02/01: PFE, MTW, CHK, BIDU High; OREX, TLB Low

FREE Breaking News Alerts from StreetInsider.com!

PFE Hot Sheet

Overall Analyst Rating:
BUY ( Down

Down)

Dividend Yield: 4.1%
EPS Growth %: -3.3%

This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today.

52-Week High:

Pfizer Inc. (NYSE: PFE) high of $19.39. Moving 6.4% to the new 52-week high, as the company put out a great earnings report and coupled it with a $5 billion stock buyback program. Q410 EPS came in at $0.47 with revs of $17.6 billion, versus the consensus EPS of $0.46 and revs of $16.97 billion. Guidance for the company wasn't anything spectacular.
Manitowoc Co. Inc. (NYSE: MTW) high of $16.94. Manitowoc shares are on rocket fuel today, shooting up over 26% today following an earnings report that saw Q410 EPS of $0.11 on revs of $830.9 million, a little mixed to the consensus EPS of $0.04 with revs of $852.87 million.
Chesapeake Energy Corporation (NYSE: CHK) high of $30.63. Up about 3.7% today following an announcement that they have inked a joint venture deal with CNOOC (NYSE: CEO) to further their Niobrara oil play in Colorado and Wyoming. CNOOC paid $570 million for a 335 share in the venture, and could pay up to an additional $697 million of the company's drilling costs. CEO McCledon made a strong case for Chesapeake to Jim Cramer yesterday as well.
Baidu, Inc. (Nasdaq: BIDU) high of $118.82. The Chinese search giant reported Q410 EPS of $0.52, ex-items, which was seven cents better than the analyst estimate of $0.45. Revenue for the quarter came in at $371.3 million versus the consensus estimate of $362.33 million. BIDU sees Q111 sales of $360.6 - $371.2 million, versus the consensus of $354.06 million. Several firms raised their price target on the stock, while Deutsche Bank upgraded the shares to Buy.

52-Week Low:

Orexigen Therapeutics, Inc. (Nasdaq: OREX) low of $2.47. Yesterday, shares closed a $9.09, today, they're about 73% to a new 52-week low following a report that had the U.S. FDA showing concern for the long-term safety profile of Contrave. Shares were also downgraded by a handful of firms today.
The Talbots Inc. (NYSE: TLB) low of $5.26. Investors continue hitting the exits on the stock, following dreary guidance on January 11, 2011. The stock has dropped over 30% since the announcement, though the stock has been on somewhat of a slide since November 2010. Shares have not been at this level since August 2009.